Core Insights - Aktis Oncology, Inc. is a clinical-stage oncology company focused on developing innovative cancer treatments, aiming to significantly impact the biotech sector [1] - The company recently completed its initial public offering (IPO), which is the first sizable offering of 2026, highlighting its growth potential and strategic positioning within the biotech industry [3] IPO Details - Aktis Oncology's IPO involved offering 17.65 million shares at $18 each, with an upsized offering that included an additional 2.65 million shares purchased by underwriters, bringing total gross proceeds to approximately $365.4 million [2] - The shares began trading on the Nasdaq Global Select Market under the ticker symbol "AKTS" on January 9, 2026 [2] Market Performance - As of the latest trading, AKTS is priced at $20.56, reflecting a slight decrease of 1.20% or $0.25, with a daily trading range between $19.69 and $21.43 [3] - Over the past year, the stock has seen a high of $29.16 and a low of $19.02, with a current market capitalization of approximately $1.08 billion and a trading volume of 234,338 shares on the NASDAQ exchange [3]